We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Lexicon Pharmaceuticals Inc | NASDAQ:LXRX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.04 | -2.17% | 1.80 | 1.80 | 1.81 | 1.85 | 1.76 | 1.85 | 1,382,350 | 18:39:21 |
|
|
|
|
|
R
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
q
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
76-0474169
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
(I.R.S. Employer
Identification Number)
|
Yes
|
þ
|
|
No
|
|
Yes
|
þ
|
|
No
|
|
Yes
|
|
|
No
|
þ
|
|
|
|
|
|
Item 6.
|
Exhibits
|
Exhibit No.
|
|
Description
|
*†10.1
|
—
|
Commercial Supply Agreement, dated June 6, 2016, with Catalent CTS, LLC
|
10.2
|
|
Sixth Amendment to Loan and Security Agreement and to Other Loan Documents, dated April 20, 2017, between Lex-Gen Woodlands, L.P. and iStar Lex Lender LLC (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K dated April 20, 2017 and incorporated by reference herein).
|
10.3
|
|
2017 Equity Incentive Plan (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K dated April 27, 2017 and incorporated by reference herein).
|
10.4
|
|
2017 Non-Employee Directors' Equity Incentive Plan (filed as Exhibit 10.2 to the Company's Current Report on Form 8-K dated April 27, 2017 and incorporated by reference herein).
|
10.5
|
|
Summary of Non-Employee Director Compensation (filed as Exhibit 10.3 to the Company's Current Report on Form 8-K dated April 27, 2017 and incorporated by reference herein).
|
*31.1
|
—
|
Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
*31.2
|
—
|
Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
*32.1
|
—
|
Certification of Principal Executive and Principal Financial Officers Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
101.INS
|
—
|
XBRL Instance Document
|
101.SCH
|
—
|
XBRL Taxonomy Extension Schema Document
|
101.CAL
|
—
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
101.DEF
|
—
|
XBRL Taxonomy Extension Definition Linkbase Document
|
101.LAB
|
—
|
XBRL Taxonomy Extension Label Linkbase Document
|
101.PRE
|
—
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
|
|
|
|
|
*
|
Filed herewith
|
|
†
|
Confidential treatment has been requested for a portion of this exhibit. The confidential portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission.
|
|
|
Lexicon Pharmaceuticals, Inc.
|
|
|
|
|
|
Date:
|
August 1, 2017
|
By:
|
/s/ Lonnel Coats
|
|
|
|
Lonnel Coats
|
|
|
|
President and Chief Executive Officer
|
|
|
|
|
Date:
|
August 1, 2017
|
By:
|
/s/ Jeffrey L. Wade
|
|
|
|
Jeffrey L. Wade
|
|
|
|
Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer
|
|
|
|
|
1 Year Lexicon Pharmaceuticals Chart |
1 Month Lexicon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions